Gliomas with IDH mutations frequently show improved responses to treatment, so these mutations are a focus of targeted therapy research, including the newly FDA-approved vorasidenib for patients with IDH-mutated gliomas [34,35]. The gene discussed is IDH1; the disease is central nervous system cancer.